FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146826939> ?p ?o ?g. }

• W2146826939 endingPage "868" @default.
• W2146826939 startingPage "859" @default.
• W2146826939 abstract "Background Ventilator-associated tracheobronchitis has been suggested as an intermediate process between tracheobronchial colonisation and ventilator-associated pneumonia in patients receiving mechanical ventilation. We aimed to establish the incidence and effect of ventilator-associated tracheobronchitis in a large, international patient cohort. Methods We did a multicentre, prospective, observational study in 114 intensive care units (ICU) in Spain, France, Portugal, Brazil, Argentina, Ecuador, Bolivia, and Colombia over a preplanned time of 10 months. All patients older than 18 years admitted to an ICU who received invasive mechanical ventilation for more than 48 h were eligible. We prospectively obtained data for incidence of ventilator-associated lower respiratory tract infections, defined as ventilator-associated tracheobronchitis or ventilator-associated pneumonia. We grouped patients according to the presence or absence of such infections, and obtained data for the effect of appropriate antibiotics on progression of tracheobronchitis to pneumonia. Patients were followed up until death or discharge from hospital. To account for centre effects with a binary outcome, we fitted a generalised estimating equation model with a logit link, exchangeable correlation structure, and non-robust standard errors. This trial is registered with ClinicalTrials.gov, number NCT01791530. Findings Between Sept 1, 2013, and July 31, 2014, we obtained data for 2960 eligible patients, of whom 689 (23%) developed ventilator-associated lower respiratory tract infections. The incidence of ventilator-associated tracheobronchitis and that of ventilator-associated pneumonia at baseline were similar (320 [11%; 10·2 of 1000 mechanically ventilated days] vs 369 [12%; 8·8 of 1000 mechanically ventilated days], p=0·48). Of the 320 patients with tracheobronchitis, 250 received appropriate antibiotic treatment and 70 received inappropriate antibiotics. 39 patients with tracheobronchitis progressed to pneumonia; however, the use of appropriate antibiotic therapy for tracheobronchitis was associated with significantly lower progression to pneumonia than was inappropriate treatment (19 [8%] of 250 vs 20 [29%] of 70, p<0·0001; crude odds ratio 0·21 [95% CI 0·11–0·41]). Significantly more patients with ventilator-associated pneumonia died (146 [40%] of 369) than those with tracheobronchitis (93 [29%] of 320) or absence of ventilator-associated lower respiratory tract infections (673 [30%] of 2271, p<0·0001). Median time to discharge from the ICU for survivors was significantly longer in the tracheobronchitis (21 days [IQR 15–34]) and pneumonia (22 [13–36]) groups than in the group with no ventilator-associated lower respiratory tract infections (12 [8–20]; hazard ratio 1·65 [95% CI 1·38–1·97], p<0·0001). Interpretation This large database study emphasises that ventilator-associated tracheobronchitis is a major health problem worldwide, associated with high resources consumption in all countries. Our findings also show improved outcomes with use of appropriate antibiotic treatment for both ventilator-associated tracheobronchitis and ventilator-associated pneumonia, underlining the importance of treating both infections, since inappropriate treatment of tracheobronchitis was associated with a higher risk of progression to pneumonia. Funding None. Ventilator-associated tracheobronchitis has been suggested as an intermediate process between tracheobronchial colonisation and ventilator-associated pneumonia in patients receiving mechanical ventilation. We aimed to establish the incidence and effect of ventilator-associated tracheobronchitis in a large, international patient cohort. We did a multicentre, prospective, observational study in 114 intensive care units (ICU) in Spain, France, Portugal, Brazil, Argentina, Ecuador, Bolivia, and Colombia over a preplanned time of 10 months. All patients older than 18 years admitted to an ICU who received invasive mechanical ventilation for more than 48 h were eligible. We prospectively obtained data for incidence of ventilator-associated lower respiratory tract infections, defined as ventilator-associated tracheobronchitis or ventilator-associated pneumonia. We grouped patients according to the presence or absence of such infections, and obtained data for the effect of appropriate antibiotics on progression of tracheobronchitis to pneumonia. Patients were followed up until death or discharge from hospital. To account for centre effects with a binary outcome, we fitted a generalised estimating equation model with a logit link, exchangeable correlation structure, and non-robust standard errors. This trial is registered with ClinicalTrials.gov, number NCT01791530. Between Sept 1, 2013, and July 31, 2014, we obtained data for 2960 eligible patients, of whom 689 (23%) developed ventilator-associated lower respiratory tract infections. The incidence of ventilator-associated tracheobronchitis and that of ventilator-associated pneumonia at baseline were similar (320 [11%; 10·2 of 1000 mechanically ventilated days] vs 369 [12%; 8·8 of 1000 mechanically ventilated days], p=0·48). Of the 320 patients with tracheobronchitis, 250 received appropriate antibiotic treatment and 70 received inappropriate antibiotics. 39 patients with tracheobronchitis progressed to pneumonia; however, the use of appropriate antibiotic therapy for tracheobronchitis was associated with significantly lower progression to pneumonia than was inappropriate treatment (19 [8%] of 250 vs 20 [29%] of 70, p<0·0001; crude odds ratio 0·21 [95% CI 0·11–0·41]). Significantly more patients with ventilator-associated pneumonia died (146 [40%] of 369) than those with tracheobronchitis (93 [29%] of 320) or absence of ventilator-associated lower respiratory tract infections (673 [30%] of 2271, p<0·0001). Median time to discharge from the ICU for survivors was significantly longer in the tracheobronchitis (21 days [IQR 15–34]) and pneumonia (22 [13–36]) groups than in the group with no ventilator-associated lower respiratory tract infections (12 [8–20]; hazard ratio 1·65 [95% CI 1·38–1·97], p<0·0001). This large database study emphasises that ventilator-associated tracheobronchitis is a major health problem worldwide, associated with high resources consumption in all countries. Our findings also show improved outcomes with use of appropriate antibiotic treatment for both ventilator-associated tracheobronchitis and ventilator-associated pneumonia, underlining the importance of treating both infections, since inappropriate treatment of tracheobronchitis was associated with a higher risk of progression to pneumonia." @default.
• W2146826939 created "2016-06-24" @default.
• W2146826939 creator A5012819390 @default.
• W2146826939 creator A5013874116 @default.
• W2146826939 creator A5021060176 @default.
• W2146826939 creator A5026158213 @default.
• W2146826939 creator A5028663302 @default.
• W2146826939 creator A5030969793 @default.
• W2146826939 creator A5032242221 @default.
• W2146826939 creator A5034004394 @default.
• W2146826939 creator A5034367911 @default.
• W2146826939 creator A5034982087 @default.
• W2146826939 creator A5041445225 @default.
• W2146826939 creator A5049743103 @default.
• W2146826939 creator A5050674173 @default.
• W2146826939 creator A5053449986 @default.
• W2146826939 creator A5060502961 @default.
• W2146826939 creator A5062118432 @default.
• W2146826939 creator A5062287721 @default.
• W2146826939 creator A5064736877 @default.
• W2146826939 creator A5075981712 @default.
• W2146826939 creator A5077160811 @default.
• W2146826939 creator A5088687424 @default.
• W2146826939 creator A5091757045 @default.
• W2146826939 date "2015-11-01" @default.
• W2146826939 modified "2023-10-18" @default.
• W2146826939 title "Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study" @default.
• W2146826939 cites W1524312738 @default.
• W2146826939 cites W1546035836 @default.
• W2146826939 cites W1898928487 @default.
• W2146826939 cites W1967834718 @default.
• W2146826939 cites W1992464091 @default.
• W2146826939 cites W1994490227 @default.
• W2146826939 cites W1996579049 @default.
• W2146826939 cites W2003821293 @default.
• W2146826939 cites W2004818381 @default.
• W2146826939 cites W2009245149 @default.
• W2146826939 cites W2014664214 @default.
• W2146826939 cites W2019349925 @default.
• W2146826939 cites W2046747986 @default.
• W2146826939 cites W2055656378 @default.
• W2146826939 cites W2057917320 @default.
• W2146826939 cites W2057995751 @default.
• W2146826939 cites W2073586753 @default.
• W2146826939 cites W2095665758 @default.
• W2146826939 cites W2099745051 @default.
• W2146826939 cites W2101237743 @default.
• W2146826939 cites W2108272771 @default.
• W2146826939 cites W2118012138 @default.
• W2146826939 cites W2120398202 @default.
• W2146826939 cites W2121690051 @default.
• W2146826939 cites W2123332024 @default.
• W2146826939 cites W2136050024 @default.
• W2146826939 cites W2151310380 @default.
• W2146826939 cites W2151895423 @default.
• W2146826939 cites W2152277089 @default.
• W2146826939 cites W2152631279 @default.
• W2146826939 cites W2163264981 @default.
• W2146826939 cites W2331267191 @default.
• W2146826939 cites W4238838602 @default.
• W2146826939 cites W4247943214 @default.
• W2146826939 doi "https://doi.org/10.1016/s2213-2600(15)00326-4" @default.
• W2146826939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26472037" @default.
• W2146826939 hasPublicationYear "2015" @default.
• W2146826939 type Work @default.
• W2146826939 sameAs 2146826939 @default.
• W2146826939 citedByCount "144" @default.
• W2146826939 countsByYear W21468269392015 @default.
• W2146826939 countsByYear W21468269392016 @default.
• W2146826939 countsByYear W21468269392017 @default.
• W2146826939 countsByYear W21468269392018 @default.
• W2146826939 countsByYear W21468269392019 @default.
• W2146826939 countsByYear W21468269392020 @default.
• W2146826939 countsByYear W21468269392021 @default.
• W2146826939 countsByYear W21468269392022 @default.
• W2146826939 countsByYear W21468269392023 @default.
• W2146826939 crossrefType "journal-article" @default.
• W2146826939 hasAuthorship W2146826939A5012819390 @default.
• W2146826939 hasAuthorship W2146826939A5013874116 @default.
• W2146826939 hasAuthorship W2146826939A5021060176 @default.
• W2146826939 hasAuthorship W2146826939A5026158213 @default.
• W2146826939 hasAuthorship W2146826939A5028663302 @default.
• W2146826939 hasAuthorship W2146826939A5030969793 @default.
• W2146826939 hasAuthorship W2146826939A5032242221 @default.
• W2146826939 hasAuthorship W2146826939A5034004394 @default.
• W2146826939 hasAuthorship W2146826939A5034367911 @default.
• W2146826939 hasAuthorship W2146826939A5034982087 @default.
• W2146826939 hasAuthorship W2146826939A5041445225 @default.
• W2146826939 hasAuthorship W2146826939A5049743103 @default.
• W2146826939 hasAuthorship W2146826939A5050674173 @default.
• W2146826939 hasAuthorship W2146826939A5053449986 @default.
• W2146826939 hasAuthorship W2146826939A5060502961 @default.
• W2146826939 hasAuthorship W2146826939A5062118432 @default.
• W2146826939 hasAuthorship W2146826939A5062287721 @default.
• W2146826939 hasAuthorship W2146826939A5064736877 @default.
• W2146826939 hasAuthorship W2146826939A5075981712 @default.
• W2146826939 hasAuthorship W2146826939A5077160811 @default.
• W2146826939 hasAuthorship W2146826939A5088687424 @default.

• next